FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078797757> ?p ?o ?g. }

• W2078797757 endingPage "788" @default.
• W2078797757 startingPage "782" @default.
• W2078797757 abstract "<h2>Abstract</h2><h3>Introduction</h3> Cediranib, a potent vascular endothelial growth factor inhibitor, demonstrated broad pre-clinical anti-tumour activity. This study evaluated escalating cediranib doses with combination chemotherapy in advanced non-small cell lung cancer patients. <h3>Methods</h3> Patients received cisplatin 80mg/m² on day 1 and gemcitabine 1250mg/m² on days 1 and 8 of a 3-week cycle, and daily oral cediranib at either 30mg or 45mg. Pharmacokinetics of all drugs were analysed, and response was assessed by RECIST. <h3>Results</h3> Fifteen patients were enrolled. No dose-limiting toxicities were observed during cycle 1. Fatigue, nausea, diarrhoea, anorexia and granulocytopaenia were common; hypertension was manageable. No grade 3/4 bleeding occurred. At 45mg/d, fatigue, diarrhoea and thrombocytopaenia were increased; and headache, hoarseness and grade 2 hand–foot syndrome were observed. Cediranib had no effect on cisplatin elimination, but clearance of gemcitabine is significantly reduced in the presence of cediranib (<i>p</i>>0.02). Central review confirmed responses in four of 15 enrolled patients (26.7%, 95% CI 7.8–55%) and four of 12 evaluable patients (33.3%, 95% CI 9.9–65%). <h3>Conclusion</h3> Cediranib at 30mg daily can be combined with standard doses of cisplatin/gemcitabine with encouraging anti-tumour activity, and is the recommended phase III dose. Toxicity is increased, but is predictable and manageable." @default.
• W2078797757 created "2016-06-24" @default.
• W2078797757 creator A5000113634 @default.
• W2078797757 creator A5007824491 @default.
• W2078797757 creator A5009677422 @default.
• W2078797757 creator A5012748795 @default.
• W2078797757 creator A5032873176 @default.
• W2078797757 creator A5044291041 @default.
• W2078797757 creator A5067772666 @default.
• W2078797757 creator A5075347427 @default.
• W2078797757 creator A5077884585 @default.
• W2078797757 date "2009-03-01" @default.
• W2078797757 modified "2023-10-02" @default.
• W2078797757 title "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group" @default.
• W2078797757 cites W1603230122 @default.
• W2078797757 cites W1989664813 @default.
• W2078797757 cites W1999966467 @default.
• W2078797757 cites W2000292756 @default.
• W2078797757 cites W2037139573 @default.
• W2078797757 cites W2043103956 @default.
• W2078797757 cites W2060298053 @default.
• W2078797757 cites W2084863129 @default.
• W2078797757 cites W2097373408 @default.
• W2078797757 cites W2100785570 @default.
• W2078797757 cites W2109134893 @default.
• W2078797757 cites W2130652363 @default.
• W2078797757 cites W2138297714 @default.
• W2078797757 cites W2139248078 @default.
• W2078797757 cites W2143695921 @default.
• W2078797757 cites W2145835533 @default.
• W2078797757 cites W2147535764 @default.
• W2078797757 cites W2149456801 @default.
• W2078797757 cites W2157769714 @default.
• W2078797757 cites W2262509800 @default.
• W2078797757 cites W3009296135 @default.
• W2078797757 cites W4243415444 @default.
• W2078797757 doi "https://doi.org/10.1016/j.ejca.2008.10.022" @default.
• W2078797757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19091548" @default.
• W2078797757 hasPublicationYear "2009" @default.
• W2078797757 type Work @default.
• W2078797757 sameAs 2078797757 @default.
• W2078797757 citedByCount "67" @default.
• W2078797757 countsByYear W20787977572012 @default.
• W2078797757 countsByYear W20787977572013 @default.
• W2078797757 countsByYear W20787977572014 @default.
• W2078797757 countsByYear W20787977572015 @default.
• W2078797757 countsByYear W20787977572016 @default.
• W2078797757 countsByYear W20787977572017 @default.
• W2078797757 countsByYear W20787977572018 @default.
• W2078797757 countsByYear W20787977572021 @default.
• W2078797757 countsByYear W20787977572022 @default.
• W2078797757 countsByYear W20787977572023 @default.
• W2078797757 crossrefType "journal-article" @default.
• W2078797757 hasAuthorship W2078797757A5000113634 @default.
• W2078797757 hasAuthorship W2078797757A5007824491 @default.
• W2078797757 hasAuthorship W2078797757A5009677422 @default.
• W2078797757 hasAuthorship W2078797757A5012748795 @default.
• W2078797757 hasAuthorship W2078797757A5032873176 @default.
• W2078797757 hasAuthorship W2078797757A5044291041 @default.
• W2078797757 hasAuthorship W2078797757A5067772666 @default.
• W2078797757 hasAuthorship W2078797757A5075347427 @default.
• W2078797757 hasAuthorship W2078797757A5077884585 @default.
• W2078797757 hasConcept C112705442 @default.
• W2078797757 hasConcept C126322002 @default.
• W2078797757 hasConcept C143998085 @default.
• W2078797757 hasConcept C197934379 @default.
• W2078797757 hasConcept C2776694085 @default.
• W2078797757 hasConcept C2778239845 @default.
• W2078797757 hasConcept C2778375690 @default.
• W2078797757 hasConcept C2780258809 @default.
• W2078797757 hasConcept C2780580376 @default.
• W2078797757 hasConcept C71924100 @default.
• W2078797757 hasConcept C90924648 @default.
• W2078797757 hasConcept C98274493 @default.
• W2078797757 hasConceptScore W2078797757C112705442 @default.
• W2078797757 hasConceptScore W2078797757C126322002 @default.
• W2078797757 hasConceptScore W2078797757C143998085 @default.
• W2078797757 hasConceptScore W2078797757C197934379 @default.
• W2078797757 hasConceptScore W2078797757C2776694085 @default.
• W2078797757 hasConceptScore W2078797757C2778239845 @default.
• W2078797757 hasConceptScore W2078797757C2778375690 @default.
• W2078797757 hasConceptScore W2078797757C2780258809 @default.
• W2078797757 hasConceptScore W2078797757C2780580376 @default.
• W2078797757 hasConceptScore W2078797757C71924100 @default.
• W2078797757 hasConceptScore W2078797757C90924648 @default.
• W2078797757 hasConceptScore W2078797757C98274493 @default.
• W2078797757 hasIssue "5" @default.
• W2078797757 hasLocation W20787977571 @default.
• W2078797757 hasLocation W20787977572 @default.
• W2078797757 hasOpenAccess W2078797757 @default.
• W2078797757 hasPrimaryLocation W20787977571 @default.
• W2078797757 hasRelatedWork W1967786039 @default.
• W2078797757 hasRelatedWork W2026791198 @default.
• W2078797757 hasRelatedWork W2085978374 @default.
• W2078797757 hasRelatedWork W2100029565 @default.
• W2078797757 hasRelatedWork W2379223378 @default.
• W2078797757 hasRelatedWork W2381460883 @default.
• W2078797757 hasRelatedWork W2383640614 @default.

• next